^
    Back
    Association details:
    Biomarker:PD-1 elevation
    Cancer:Renal Cell Carcinoma
    Drug:sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Oncoimmunology
    Title:

    Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma

    Published date:
    11/25/2020
    Excerpt:
    mccRCC patients with high plasmatic levels of sPD-L1 or sPD-1 are poor responders to sunitinib.
    DOI:
    10.1080/2162402X.2020.1846901